The treatment for ventricular tachycardia (VTach) depends entirely on whether the patient has a pulse and whether they’re hemodynamically stable. A patient in pulseless VTach gets immediate defibrillation and CPR, just like ventricular fibrillation. A patient with a pulse but signs of instability gets synchronized cardioversion. And a stable patient with a pulse gets antiarrhythmic medications as the first intervention. Getting this triage right is the single most important step.
Pulseless VTach: Defibrillation First
Pulseless VTach is treated identically to ventricular fibrillation. The priority is high-quality CPR and unsynchronized defibrillation. On a biphasic defibrillator, the initial shock is typically 120 to 200 joules (follow the manufacturer’s recommendation for the specific device). On a monophasic defibrillator, start at 360 joules. Each successive shock should be equal to or greater than the previous one until the maximum available energy is reached.
After the first shock, resume CPR immediately for two minutes before reassessing the rhythm. If pulseless VTach persists after the second shock and another round of CPR, it’s time to add medications. Amiodarone is the first-line drug in cardiac arrest: 300 mg as an initial bolus, followed by a second dose of 150 mg if needed. If amiodarone isn’t available, lidocaine is the alternative at 1 to 1.5 mg/kg for the first dose, with repeat doses of 0.5 to 0.75 mg/kg.
Unstable VTach With a Pulse
If the patient has a pulse but shows signs of hemodynamic instability (hypotension, altered mental status, chest pain, or signs of heart failure), the treatment is synchronized cardioversion. Unlike defibrillation, synchronized cardioversion times the shock to the heart’s electrical cycle, which reduces the risk of triggering a worse rhythm.
Start at 50 joules. If the first shock doesn’t convert the rhythm, double the energy for each subsequent attempt. After just three escalating shocks, you can reach 200 joules if needed. Sedation should be provided before cardioversion whenever the clinical situation allows it.
Stable VTach With a Pulse
A hemodynamically stable patient in VTach can be treated with antiarrhythmic medications before resorting to electrical therapy. The two drugs most commonly used in this scenario are amiodarone and procainamide, with the choice depending on the clinical context and the patient’s underlying heart function.
Amiodarone is widely considered the most important emergency antiarrhythmic for ventricular arrhythmias. The dose for a patient with a pulse is 150 mg given intravenously over 10 minutes, which can be repeated if VTach recurs. This is followed by a maintenance infusion of 1 mg/min for the first six hours, then reduced to 0.5 mg/min for the next 18 hours. Amiodarone should not be used in patients with significantly prolonged QT intervals, as it can paradoxically worsen the arrhythmia in that setting.
Procainamide is an alternative that’s particularly useful for stable, wide-complex tachycardias. The loading dose is 10 to 17 mg/kg, infused at a rate of 20 to 50 mg/min. Three specific endpoints signal when to stop the infusion: the arrhythmia terminates, the QRS complex widens by 50% from its original width, or hypotension develops. Procainamide is contraindicated in patients with heart failure or a prolonged QT interval.
The Role of Beta-Blockers
Blocking the body’s adrenaline response is a cornerstone of managing ventricular arrhythmias. Heightened sympathetic activity, the “fight or flight” response, can both trigger and sustain VTach. Short-acting beta-blockers are especially valuable in electrical storm, a condition where VTach recurs repeatedly despite standard treatment. In cases where amiodarone alone fails to control recurrent episodes, a short-acting beta-blocker given as a continuous infusion has been shown to stabilize heart rhythm even in patients with severely reduced heart function.
Lidocaine: Best for Ischemia-Related VTach
Lidocaine occupies a specific niche. It’s less potent than amiodarone for most types of VTach, but it works particularly well when the arrhythmia is triggered by active cardiac ischemia (a heart attack in progress). The drug binds more effectively to heart tissue in low-oxygen, acidic conditions, which is exactly what happens during ischemia. The initial dose is 1 to 1.5 mg/kg as a bolus, with additional boluses of 0.5 to 0.75 mg/kg every 5 to 10 minutes up to a maximum of 3 mg/kg, followed by a maintenance infusion. Lidocaine is generally reserved for situations where amiodarone is ineffective or contraindicated.
Torsades de Pointes: Magnesium First
Torsades de Pointes is a specific subtype of VTach with a distinctive “twisting of the points” pattern on the monitor, typically occurring in the setting of a prolonged QT interval. Standard antiarrhythmics like amiodarone can actually make Torsades worse because they further prolong the QT interval. The first-line treatment is intravenous magnesium sulfate: a slow 2-gram IV push, followed by an infusion of 1 to 4 grams per hour. The infusion continues until magnesium blood levels exceed a therapeutic threshold, at which point it can be stopped. If the patient is unstable or pulseless, defibrillation still takes priority.
Checking for Reversible Causes
Regardless of which drug or electrical therapy is used, identifying and correcting the underlying trigger is essential. The classic framework organizes reversible causes into two groups. The “H’s” include low blood volume (hypovolemia), low oxygen levels (hypoxia), too much or too little hydrogen ion in the blood (acidosis or alkalosis), low potassium or other electrolyte imbalances, and low body temperature (hypothermia). The “T’s” include tension pneumothorax, cardiac tamponade, toxins or drug overdoses, blood clots in the lungs (pulmonary embolism), and blood clots in the coronary arteries (heart attack).
Electrolyte correction deserves special attention. Low potassium and low magnesium are among the most common correctable triggers for VTach. Replacing these aggressively can make the difference between a rhythm that responds to treatment and one that keeps recurring.
Pediatric VTach Dosing
Children use the same drugs but at weight-based doses. Amiodarone is given at 5 mg/kg IV, which can be repeated up to twice for a maximum total of 15 mg/kg (with a single-dose cap of 300 mg). In a child with a pulse, the infusion should be given slowly over 20 to 60 minutes rather than as a rapid push. Lidocaine is dosed at 1 mg/kg as a bolus. Expert consultation is strongly recommended before giving antiarrhythmics to a child who has a perfusing rhythm, and particular caution applies when combining drugs that affect the QT interval.